IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2017

Aryl Hydrocarbon Receptor and Lung Cancer.
J.J. TSAY, K.-M. TCHOU-WONG, A.K. GREENBERG, H. PASS, W.N. ROM (New York, NY, USA). Anticancer Res 33: 1247. 2013
Radiotherapy Targeting Cancer Stem Cells: Current Views and Future Perspectives.
K. OGAWA, Y. YOSHIOKA, F. ISOHASHI, Y. SEO, K. YOSHIDA, H. YAMAZAKI (Osaka; Kyoto, Japan). Anticancer Res 33: 747. 2013
Genistein and Daidzein: Different Molecular Effects on Prostate Cancer.
M. ADJAKLY, M. NGOLLO, J.-P. BOITEUX, Y.-J. BIGNON, L. GUY, D. BERNARD-GALLON (Clermont-Ferrand, France). Anticancer Res 33: 39. 2013
Vaginal Intraepithelial Neoplasia: A Therapeutical Dilemma.
A. FREGA, F. SOPRACORDEVOLE, C. ASSORGI, D. LOMBARDI, V. DE SANCTIS, A. CATALANO, E. MATTEUCCI, G.N. MILAZZO, E. RICCIARDI, M. MOSCARINI (Rome; Aviano, Italy). Anticancer Res 33: 29. 2013
The Mammalian Target of Rapamycin Inhibitors in Breast Cancer: Current Evidence and Future Directions.
P. MALAGUTI, S. VARI, F. COGNETTI, A. FABI (Rome, Italy). Anticancer Res 33: 21. 2013
Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting.
S. GANAPATHY-KANNIAPPAN, R. KUNJITHAPATHAM, J.-F. GESCHWIND (Baltimore, MD, USA). Anticancer Res 33: 33. 2013
Neurofibromatosis Type 2 Protein, NF2: An Uncoventional Cell Cycle Regulator.
S. BELTRAMI, R. KIM, J. GORDON (Philadelphia, PA, USA). Anticancer Res 33: 1.2013). Anticancer Res 33: 1. 2013
HSP-Molecular Chaperones in Cancer Biogenesis and Tumor Therapy: An Overview.
F. RAPPA, F. FARINA, G. ZUMMO, S. DAVID, C. CAMPANELLA, F. CARINI, G. TOMASELLO, P. DAMIANI, F. CAPPELLO, E.C. DE MACARIO, A.J.L. MACARIO (Palermo, Italy; Baltimore, MD, USA). Anticancer Res 32: 5139
Recent Trends in Epidemiology of Brain Metastases: An Overview.
E. TABOURET, O. CHINOT, P.METELLUS, A. TALLET, P. VIENS, A. GONÇALVES (Marseille, France). Anticancer Res 32: 4655
Biomarkers of Pituitary Neoplasms.
A. SAV, F. ROTONDO, L.V. SYRO, B.W. SCHEITHAUER, K. KOVACS (Istanbul, Turkey; Toronto, ON, Canada; Medellin, Colombia; Rochester, MN, USA). Anticancer Res 32: 4639
Utility of Hypertension as a Surrogate Marker for Efficacy of Antiangiogenic Therapy in NSCLC.
T. EVANS (Philadelphia, PA, USA). Anticancer Res 32: 4629
Mind the Gap; Regulation of Gap Junctional, Intercellular Communication by the Src OncogeneProduct and its Effectors.
M. GELETU, A. TROTMAN-GRANT, L. RAPTIS (Kingston, ON,Canada). Anticancer Res 32: 4245
Markers for Efficacy of Mammalian Target of Rapamycin Inhibitor.
Y.-M. LIAO, A. SY, Y. YEN (Taichung; * Taipei, Taiwan, ROC; Duarte, CA, USA). Anticancer Res 32: 4235
Regulation of Cancer Cell Survival by BCL2 Family Members upon Prolonged Mitotic Arrest: Opportunities * for Anticancer Therapy.
S. BARILLÉ-NION, N. BAH, E. VÉQUAUD, P. JUIN (Nantes; Saint Herblain-Nantes, France). Anticancer Res 32: 4225
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma:
A Brief Overview of Current Clinical Results. C. SCARINGI, G. MINNITI, P. CAPORELLO, R.M. ENRICI (Rome; Pozzilli, Italy). Anticancer Res 32: 4213
Viral and Molecular Aspects of Oral Cancer.
N.S. HILLBERTZ, J.-M. HIRSCH, J. JALOULI, M.M. JALOULI, L. SAND (Uppsala, Sweden). Anticancer Res 32: 4201
New Perspectives in the Treatment of Neuroendocrine Tumours.
E. BAJETTA, L. CATENA, M. VALENTE, N. BIANCO, F. BELLOMO, E. BOMBARDIERI (Monza; Milan, Italy). Anticancer Res 32: 4193
Nutrition in Adult and Childhood Cancer: Role of Carcinogens and Anti-carcinogens.
T.T. MOSBY, M. COSGROVE, S. SARKARDEI, K.L. PLATT, B. KAINA (Memphis, TN, USA; Mainz, Germany). Anticancer Res 32: 4171
The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer.
L. HOLUBEC, V.LISKA, V.M. MATEJKA, O. FIALA, J. DRESLEROVA, P. MRAZKOVA, V. TRESKA, J. FINEK(Prague, Czech Republic). Anticancer Res 32: 4007
A Review of Dose-dense Temozolomide Alone and in Combination with Bevacizumab in Patients with First Relapse of Glioblastoma.
F. JOHANSSON, S. EKMAN, E. BLOMQUIST, R. HENRIKSSON, S. BERGSTRØM, M. BERGQVIST (Uppsala; Umeå; Stockholm; Gävle, Sweden). Anticancer Res 32: 4001
Prediction of Recurrence after Complete Resection in Patients with NSCLC.
H. URAMOTO, F. TANAKA (Kitakyushu, Japan). Anticancer Res 32: 3953
Update on PEG-Interferon α-2b as Adjuvant Therapy in Melanoma.
R. DI TROLIO, E. SIMEONE,G. DI LORENZO, A.M. GRIMALDI, A. ROMANO, F. AYALA, C. CARACÒ, N. MOZZILLO, P.A. ASCIERTO (Naples, Italy). Anticancer Res 32: 3901
MicroRNAs in Renal Cell Carcinoma: Implications for Pathogenesis, Diagnosis, Prognosis andTherapy.
B.M. AL-ALI, A.L. RESS, A. GERGER, M. PICHLER (Graz, Austria). Anticancer Res 32: 3727
From Development to Cancer: Lessons from the Kidney to Uncover New Therapeutic Targets.
V. DORMOY, D. JACQMIN, H. LANG, T. MASSFELDER (Strasbourg, France). Anticancer Res 32: 3609
Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer.
G. SECRETO, B. ZUMOFF (Milan, Italy; New York, NY, USA). Anticancer Res 32: 3223
Tumor Progression and Metastasis: Role of Translational Deregulation.
Z. NASR, J. PELLETIER(Montreal, QC, Canada). Anticancer Res 32: 3077
Sex Steroids and Cervical Cancer.
D. HELLBERG (Falun, Sweden). Anticancer Res 32: 3045
New Anticancer Agents: Recent Developments in Tumor Therapy.
R. ALI, Z. MIRZA, G.M.D. ASHRAF, M.A. KAMAL, S.A. ANSARI, G.A. DAMANHOURI, A.M. ABUZENADAH, A.G. CHAUDHARY, I.A. SHEIKH (New Delhi, India; Jeddah, Kingdom of Saudi Arabia). Anticancer Res 32: 2999
The Potential of RECK Inducers as Antitumor Agents for Glioma.
Y. CHEN, S.-H. TSENG (NewTaipei; Taoyuan; Taipei, Taiwan, ROC). Anticancer Res 32: 2991
Inhibitors of Bacterial Efflux Pumps that also Inhibit Efflux Pumps of Cancer Cells.
L. AMARAL,G. SPENGLER, A. MARTINS, A. ARMADA, J. HANDZLIK, K. KIEC-KONONOWICZ, J. MOLNÁR(Lisbon; Krakow, Portugal; Szeged, Hungary). Anticancer Res 32: 2947
New Molecularly Targeted Therapies for Glioblastoma Multiforme.
J. POLIVKA JR., J. POLIVKA,V. ROHAN, O. TOPOLCAN, J. FERDA (Pilsen, Czech Republic). Anticancer Res 32: 2935
Mafosfamide as a New Anticancer Agent: Preclinical Investigations and Clinical Trials.
L. MAZUR, M. OPYDO-CHANEK, M. STOJAK, K. WOJCIESZEK (Kracow, Poland). Anticancer Res 32: 2783
New Frontiers for Astrocytic Tumours.
R. NANO, A. LASCIALFARI, M. CORTI, A. PAOLINI, F. PASI, F. CORBELLA, R. DI LIBERTO (Pavia; Milan, Italy). Anticancer Res 32: 2755
Role of Melatonin in Cancer Treatment.
A. CUTANDO, A. LÓPEZ-VALVERDE, S. ARIAS- SANTIAGO, J. DE VICENTE, R. GÓMEZ DE DIEGO (Granada; Salamanca; Madrid, Spain). Anticancer Res 32: 2747
Tumor Cell-protective Catalase as a Novel Target for Rational Therapeutic Approaches Based on Specific Intercellular ROS Signaling.
G. BAUER (Freiburg, Germany). Anticancer Res 32: 2599
New Therapeutic Agents in Uveal Melanoma.
T.R. VELHO, E. KAPITEIJN, M.J. JAGER (Leiden, Netherlands). Anticancer Res 32: 2591
A Significant Role of Lipogenic Enzymes in Colorectal Cancer.
M. NOTARNICOLA, C. MESSA,M.G. CARUSO (Bari, Italy). Anticancer Res 32: 2585
Death by Design: Where Curcumin Sensitizes Drug-resistant Tumours.
S. SAHA, A. ADHIKARY,P. BHATTACHARYYA, T. DAS, G. SA (Kolkata, India). Anticancer Res 32: 2567
New Anticancer Agents: Hormones Made within the Heart.
D.L. VESELY (Tampa, FL, USA). Anticancer Res 32: 2515
Novel Radiosensitizing Anticancer Therapeutics.
A.G. LINKOUS, E.M. YAZLOVITSKAYA(Bethesda, MD; Nashville, TN, USA). Anticancer Res 32: 2487
Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders.
M. ROGOSNITZKY, R. DANKS, E. KARDASH (Telz Stone, Israel; Steep, UK). Anticancer Res 32: 2471
PI3 Kinase Inhibitors in the Clinic: An Update.
J.-E. KURTZ, I. RAY-COQUARD (Strasbourg; Lyon, France). Anticancer Res 32: 2463
New Anticancer Immunotherapies.
H.A. FRANKS, Q. WANG, P.M. PATEL (Nottingham, UK). Anticancer Res 32: 2439
Novel Approaches in the Pharmacotherapy of Skeletal-related Events in Metastatic Castrate-resistant Prostate Cancer.
S. SPENCER, B.L. MARINI, W.D. FIGG (Bethesda, MD; Ann Arbor, MI, USA). Anticancer Res 32: 2391
Functional Design of Chimeric T-Cell Antigen Receptors for Adoptive Immunotherapy of Cancer:Architecture and Outcomes.
N. SHIRASU, M. KUROKI (Fukuoka, Japan). Anticancer Res 32: 2377
Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer.
K. MIYATA, F. YOTSUMOTO, S.O. NAM, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan). Anticancer Res 32: 2347
The Involvement of O-Antigen Polysaccharide in Lipopolysaccharide in Macrophage Activation.
M. SHIMADA, T. KADOWAKI, Y. TANIGUCHI, H. INAGAWA, K. OKAZAKI, G.-I. SOMA (Kagawa; Tokushima, Japan). Anticancer Res 32: 2337
Heat-shock Protein 27 Plays the Key Role in Gemcitabine-resistance of Pancreatic Cancer Cells.
Y. KURAMITSU, Y. WANG, K. TABA, S. SUENAGA, S. RYOZAWA, S. KAINO, I. SAKAIDA, K. NAKAMURA (Yamaguchi, Japan). Anticancer Res 32: 2295
Endometrial Cancer Stem Cells: A New Target for Cancer Therapy.
K. KATO (Tokyo, Japan). Anticancer Res 32: 2283
Reconsideration of Macrophage and Dendritic Cell Classification.
T. KADOWAKI, M. SHIMADA, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA (Kagawa; Chiba; Tokushima, Japan). Anticancer Res 32: 2257
Page: 1 2 3 4 5 6 ... 7 8 9 10 
Custom Tables Plugin 05a1a29bdcae7b12229e651a9fd48b11

IMPORTANT NOTE: You may submit your article only through our online submission system